Affinity Asset Advisors 13F annual report
Affinity Asset Advisors is an investment fund managing more than $474 billion ran by Jonathan Chu. There are currently 70 companies in Mr. Chu’s portfolio. The largest investments include Immunogen and Cerevel Therapeutics Hldng I, together worth $73.4 billion.
$474 billion Assets Under Management (AUM)
As of 6th February 2024, Affinity Asset Advisors’s top holding is 1,404,608 shares of Immunogen currently worth over $41.6 billion and making up 8.8% of the portfolio value.
Relative to the number of outstanding shares of Immunogen, Affinity Asset Advisors owns more than approximately 0.1% of the company.
In addition, the fund holds 750,000 shares of Cerevel Therapeutics Hldng I worth $31.8 billion.
The third-largest holding is Cymabay Therapeutics Inc worth $25.8 billion and the next is Madrigal Pharmaceuticals Inc worth $23.1 billion, with 100,000 shares owned.
Currently, Affinity Asset Advisors's portfolio is worth at least $474 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Affinity Asset Advisors
The Affinity Asset Advisors office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Jonathan Chu serves as the Chief Compliance Officer at Affinity Asset Advisors.
Recent trades
In the most recent 13F filing, Affinity Asset Advisors revealed that it had opened a new position in
Immunogen and bought 1,404,608 shares worth $41.6 billion.
This means they effectively own approximately 0.1% of the company.
Immunogen makes up
14.0%
of the fund's Health Care sector allocation and has grown its share price by 617.9% in the past year.
The investment fund also strengthened its position in Cerevel Therapeutics Hldng I by buying
200,000 additional shares.
This makes their stake in Cerevel Therapeutics Hldng I total 750,000 shares worth $31.8 billion.
On the other hand, there are companies that Affinity Asset Advisors is getting rid of from its portfolio.
Affinity Asset Advisors closed its position in Chinook Therapeutics on 13th February 2024.
It sold the previously owned 321,017 shares for $12.3 billion.
Jonathan Chu also disclosed a decreased stake in Autolus Therapeutics plc by approximately 0.1%.
This leaves the value of the investment at $9.98 billion and 1,550,408 shares.
One of the average hedge funds
The two most similar investment funds to Affinity Asset Advisors are Mraz, Amerine & Associates and Townsend & Associates, Inc. They manage $474 billion and $474 billion respectively.
Jonathan Chu investment strategy
Affinity Asset Advisors’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 62.8% of
the total portfolio value.
The fund focuses on investments in the United States as
50.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
4% of the total holdings value.
On the other hand, large-cap stocks make up only 2.9% of the portfolio.
The average market cap of the portfolio companies is close to $6.66 billion.
The complete list of Affinity Asset Advisors trades based on 13F SEC filings
These positions were updated on February 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Immunogen, Inc. |
Opened
1,404,608
|
$41,646,627,000 | 8.79% |
| Cerevel Therapeutics Hldng I |
36.36%
750,000
|
$31,800,000,000 | 6.71% |
| Cymabay Therapeutics Inc |
3.84%
1,090,441
|
$25,756,216,000 | 5.43% |
| Madrigal Pharmaceuticals Inc |
8.11%
100,000
|
$23,138,000,000 | 4.88% |
| Xenon Pharmaceuticals Inc |
661.89%
460,000
|
$21,187,600,000 | 4.47% |
| Teva Pharmaceutical Inds Ltd |
18.75%
1,900,000
|
$19,836,000,000 | 4.19% |
| Arcellx Inc |
50.26%
340,000
|
$18,870,000,000 | 3.98% |
| Lianbio |
372.06%
3,779,694
|
$16,895,232,000 | 3.56% |
| Crinetics Pharmaceuticals In |
Opened
447,095
|
$15,907,640,000 | 3.36% |
| Celldex Therapeutics Inc. |
359.61%
400,000
|
$15,864,000,000 | 3.35% |
| Apogee Therapeutics Inc |
Opened
537,093
|
$15,006,378,000 | 3.17% |
| Immunovant Inc |
32.69%
345,000
|
$14,534,850,000 | 3.07% |
| Cytokinetics Inc |
27.85%
160,000
|
$13,358,400,000 | 2.82% |
| Nuvalent Inc |
Opened
175,000
|
$12,878,250,000 | 2.72% |
| Chinook Therapeutics, Inc. |
Closed
321,017
|
$12,333,473,000 | |
| Biogen Inc |
Closed
40,000
|
$11,394,000,000 | |
| Astria Therapeutics Inc |
125.31%
1,466,465
|
$11,262,451,000 | 2.38% |
| Verona Pharma Plc |
25.95%
563,824
|
$11,208,821,000 | 2.36% |
| Spyre Therapeutics Inc |
Opened
517,554
|
$11,137,762,000 | 2.35% |
| Autolus Therapeutics plc |
2.43%
1,550,408
|
$9,984,628,000 | 2.11% |
| Alkermes plc |
Opened
356,384
|
$9,886,092,000 | 2.09% |
| Inozyme Pharma, Inc. |
150.84%
1,885,802
|
$8,033,517,000 | 1.69% |
| Nurix Therapeutics, Inc. |
590.11%
690,112
|
$7,121,956,000 | 1.50% |
| Prothena Corp Plc |
Closed
100,000
|
$6,828,000,000 | |
| Centessa Pharmaceuticals Plc |
11.66%
795,729
|
$6,334,003,000 | 1.34% |
| Establishment Labs Holdings Inc |
7.88%
228,277
|
$5,910,092,000 | 1.25% |
| Mirati Therapeutics Inc |
Opened
100,049
|
$5,877,879,000 | 1.24% |
| Roivant Sciences Ltd |
Opened
500,000
|
$5,615,000,000 | 1.18% |
| Viking Therapeutics Inc |
No change
300,000
|
$5,583,000,000 | 1.18% |
| Savara Inc |
Opened
1,150,000
|
$5,405,000,000 | 1.14% |
| COMPASS Pathways plc |
Opened
550,000
|
$4,812,500,000 | 1.02% |
| Apellis Pharmaceuticals Inc |
650.00%
75,000
|
$4,489,500,000 | 0.95% |
| Moonlake Immunotherapeutics |
Opened
70,988
|
$4,286,965,000 | 0.90% |
| Dynavax Technologies Corp. |
Opened
300,000
|
$4,194,000,000 | 0.88% |
| Astrazeneca plc |
No change
60,000
|
$4,041,000,000 | 0.85% |
| Axsome Therapeutics Inc |
300.00%
50,000
|
$3,979,500,000 | 0.84% |
| SpringWorks Therapeutics, Inc. |
23.08%
100,000
|
$3,650,000,000 | 0.77% |
| Relay Therapeutics, Inc. |
Opened
300,000
|
$3,303,000,000 | 0.70% |
| Ventyx Biosciences Inc |
Closed
100,696
|
$3,302,829,000 | |
| BridgeBio Pharma Inc |
127.71%
80,000
|
$3,229,600,000 | 0.68% |
| Krystal Biotech Inc |
Opened
25,000
|
$3,101,500,000 | 0.65% |
| Cullinan Oncology, LLC |
Opened
300,000
|
$3,057,000,000 | 0.64% |
| Tango Therapeutics Inc |
Opened
300,274
|
$2,972,713,000 | 0.63% |
| Reata Pharmaceuticals Inc |
Closed
29,105
|
$2,967,546,000 | |
| Argenx Se |
Opened
7,500
|
$2,853,225,000 | 0.60% |
| Kura Oncology Inc |
78.96%
191,535
|
$2,754,273,000 | 0.58% |
| FibroGen Inc |
Closed
983,300
|
$2,654,910,000 | |
| EyePoint Pharmaceuticals Inc |
Opened
109,900
|
$2,539,789,000 | 0.54% |
| Ascendis Pharma A/S |
65.37%
20,000
|
$2,519,000,000 | 0.53% |
| Mersana Therapeutics Inc |
Opened
1,000,000
|
$2,320,000,000 | 0.49% |
| Theseus Pharmaceuticals Inc |
Closed
240,244
|
$2,241,477,000 | |
| Aeglea BioTherapeutics Inc |
Closed
4,900,000
|
$2,207,450,000 | |
| Immatics N.v |
33.33%
200,000
|
$2,106,000,000 | 0.44% |
| Vincerx Pharma Inc |
Closed
1,492,771
|
$1,940,602,000 | |
| Penumbra Inc |
Opened
7,500
|
$1,886,550,000 | 0.40% |
| Tourmaline Bio Inc |
Opened
68,081
|
$1,782,361,000 | 0.38% |
| ADC Therapeutics SA |
68.92%
1,013,540
|
$1,682,476,000 | 0.35% |
| Cabaletta Bio Inc |
Closed
125,000
|
$1,613,750,000 | |
| Vaxcyte, Inc. |
79.56%
25,000
|
$1,570,000,000 | 0.33% |
| KalVista Pharmaceuticals Inc |
29.35%
125,969
|
$1,543,120,000 | 0.33% |
| Mirum Pharmaceuticals Inc |
66.67%
50,000
|
$1,476,000,000 | 0.31% |
| Newamsterdam Pharma Company |
25.00%
125,000
|
$1,396,250,000 | 0.29% |
| Neurocrine Biosciences, Inc. |
Opened
10,000
|
$1,317,600,000 | 0.28% |
| Inari Med Inc |
Opened
20,000
|
$1,298,400,000 | 0.27% |
| Allogene Therapeutics Inc |
Opened
400,000
|
$1,284,000,000 | 0.27% |
| Aadi Bioscience Inc |
Closed
187,675
|
$1,283,697,000 | |
| Aldeyra Therapeutics Inc |
Closed
150,000
|
$1,258,500,000 | |
| Morphic Hldg Inc |
78.86%
42,670
|
$1,232,310,000 | 0.26% |
| Alpine Immune Sciences Inc |
Closed
118,891
|
$1,222,199,000 | |
| Viridian Therapeutics Inc |
Opened
50,000
|
$1,089,000,000 | 0.23% |
| Mineralys Therapeutics Inc |
Closed
62,500
|
$1,065,625,000 | |
| BioAtla, Inc. |
Closed
325,000
|
$975,000,000 | |
| Biohaven Ltd |
Opened
20,866
|
$893,065,000 | 0.19% |
| Puma Biotechnology Inc |
No change
202,349
|
$876,171,000 | 0.18% |
| Milestone Pharmaceuticals In |
Closed
300,068
|
$855,194,000 | |
| Fulcrum Therapeutics Inc |
Opened
125,000
|
$843,750,000 | 0.18% |
| AvroBio Inc |
Opened
500,000
|
$680,000,000 | 0.14% |
| Jasper Therapeutics Inc |
Closed
476,948
|
$653,419,000 | |
| Talaris Therapeutics Inc |
Closed
200,000
|
$608,000,000 | |
| Immatics N.v |
Opened
187,204
|
$546,636,000 | 0.12% |
| Vir Biotechnology Inc |
Closed
20,000
|
$490,600,000 | |
| Spdr S&p 500 Etf Tr |
Closed
18,087
|
$488,256,000 | |
| Nls Pharmaceutics Ltd |
Closed
400,000
|
$440,000,000 | |
| Newamsterdam Pharma Company |
Opened
137,000
|
$428,810,000 | 0.09% |
| Terns Pharmaceuticals Inc |
Opened
66,000
|
$428,340,000 | 0.09% |
| Nuvation Bio Inc |
No change
250,000
|
$377,500,000 | 0.08% |
| Context Therapeutics Inc |
22.89%
328,817
|
$371,563,000 | 0.08% |
| Inflarx Nv |
16.70%
200,097
|
$326,158,000 | 0.07% |
| Promis Neurosciences Inc |
Opened
265,958
|
$305,852,000 | 0.06% |
| Aravive Inc |
Opened
346,511
|
$42,863,000 | 0.01% |
| Rocket Pharmaceuticals Inc |
Opened
75,000
|
$36,750,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 91 holdings | |||
Hedge funds similar to Affinity Asset Advisors
- Raub Brock Capital Management L.P.
- Tufton Capital Management
- Mcilrath & Eck
- Madison Wealth Management
- Onyx Bridge Wealth
- Land & Buildings Investment Management
- Mitchell Capital Management Co
- Mraz, Amerine & Associates
- Townsend & Associates, Inc
- Pensionmark
- Thomas White International Ltd
- Elwood & Goetz Wealth Advisory
- Baron Silver Stevens Financial Advisors
- Academy Capital Management Inc/tx